Skip to content

Press Releases

NeonMind Announces Consolidation

January 19, 2023 Oakville, Ontario – January 19, 2023: NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink: NMDBF) (FRA:6UF0) (“NeonMind” or the “Company”) announces that, in preparation for a reverse merger transaction with Lancaster Lithium Inc. (“Lancaster Lithium”) as previously announced

Read More »

NeonMind Announces Cancellation of Securities

January 11, 2023 Oakville, Ontario – January 11, 2023: NeonMind Biosciences Inc. (CSE: NEON) (FRA:6UF0) (“NeonMind” or the “Company”) announces that, in preparation for the reverse merger transaction with Lancaster Lithium Inc. previously announced on December 14, 2022, NeonMind has

Read More »

NeonMind Announces Management Change

December 9, 2022 Oakville, Ontario – December 9, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink:NMDBF) (FSE:6UF) (“NeonMind” or the “Company”) announced today that Rob Tessarolo, a director on the NeonMind Board of Directors, was appointed Chief Executive Officer and

Read More »

NeonMind Announces Organizational Changes

May 30, 2022 6:00pm EDT Oakville, Ontario – May 30, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF0) (“NeonMind” or the “Company”) announced today that has made changes to its Management, Board of Directors and Advisory Board to support

Read More »

NeonMind Engages Leading Digital Platform for Medical Education and Adoption of Ketamine Treatments in Preparation of Opening its Inaugural Specialty Mental Health Clinic

April 11, 2021 8:00am EDT Initiates Medical Adoption Program with Impetus Digital, a Leading Healthcare Platform for Virtual Medical Education OAKVILLE, ON / ACCESSWIRE / April 19, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBD)(FRA:6UF) (“NeonMind” or the “Company“), an integrated drug development

Read More »

NeonMind Announces Share Consolidation

April 11, 2021 8:00am EDT Oakville, Ontario – April 11, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”) an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from

Read More »

NeonMind Closes Convertible Debenture Financing

April 08, 2021 8:00am EDT Oakville, Ont. – April 8, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”) an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from

Read More »

en_USEnglish